Evidence map›Paper›PMID 41898448›Full record

ArticleInternational journal of molecular sciences2026

Stalling the Enemy: Targeting Nsp13 for Next-Generation SARS-CoV-2 Antivirals.

Jose M Castro, Ryan L Slack, Yee T Ong, Huanchun Zhang, Levi B Gifford, Valentine V Courouble, Riley M Aiken, Vishal Shankar, Timothy R O'Leary, Patrick R Griffin and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Special Issue "Antiviral Drugs Discovery".International journal of molecular sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jose M CastroCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0002-4002-4475
Ryan L SlackCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Yee T OngCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Huanchun ZhangCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Levi B GiffordCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Valentine V CouroubleThe Herbert Wertheim Scripps Institute for Biomedical Innovation and Technology, University of Florida Health, Jupiter, FL 33458, USA.
Riley M AikenCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Vishal ShankarCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Timothy R O'LearyThe Herbert Wertheim Scripps Institute for Biomedical Innovation and Technology, University of Florida Health, Jupiter, FL 33458, USA.
Patrick R GriffinThe Herbert Wertheim Scripps Institute for Biomedical Innovation and Technology, University of Florida Health, Jupiter, FL 33458, USA.
Shuiyun LanCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Yuhong DuDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Haian FuDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Stefan G SarafianosCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.

Funding

Discovery of SARS-CoV-2 antivirals using a replicon assayR01AI167356 · NIAID · EMORY UNIVERSITY · PI Stefan G Sarafianos, Zhengqiang Wang · 2022 to 2026
$3.5M
Emory Training Program in Translational Research to End the HIV EpidemicT32AI157855 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2021 to 2026
$2.8M
Training Program in Biochemistry, Cell and Molecular BiologyT32GM135060 · NIGMS · EMORY UNIVERSITY · PI Lawrence H. Boise, ANITA H. CORBETT · 2020 to 2026
$2.8M
National Institute of Allergy and Infectious Diseases R01 AI167356-03S1NIAID NIH HHS R01 AI167356NIAID NIH HHS T32 AI157855NIGMS NIH HHS T32 GM135060
6 · The paper itself

Abstract

The SARS-CoV-2 public health challenges have highlighted the urgent need for coronavirus-targeting life-saving therapeutics. Given the emergence of drug-resistant strains, the development of antivirals against viral proteins beyond the commonly targeted main protease or RNA-dependent RNA polymerase is critical. The SARS-CoV-2 nonstructural protein 13 (nsp13) is a highly conserved RNA helicase and an essential component of the viral replication-transcription complex (RTC). It unwinds double-stranded RNA to facilitate viral transcription and replication, making it a strong target for drug development. To identify nsp13 inhibitors, we used an ultra-high-throughput nucleic acid unwinding assay to screen a library of FDA-approved drugs and bioactive compounds. We identified forty inhibitors with IC

Indexed as

Antiviral AgentsBetacoronavirusRNA HelicasesSARS-CoV-2Viral Nonstructural ProteinsCOVID-19 Drug TreatmentHumansMethyltransferasesVirus ReplicationAntiviral AgentsMethyltransferasesNsp13 protein, SARS-CoVRNA HelicasesViral Nonstructural ProteinsantiviralHDXhelicaseHTSNsp13repliconSARS-CoV-2

Identifiers

PMID41898448
PMCPMC13027058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.